Sung Han Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3204316/publications.pdf

Version: 2024-02-01

108 1,296 19 28
papers citations h-index g-index

109 109 109 2231 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors. The Korean Journal of Urological Oncology, 2022, 20, 25-33.	0.1	O
2	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer. The Korean Journal of Urological Oncology, 2022, 20, 1-11.	0.1	1
3	Targeted Inhibition of O-Linked \hat{l}^2 -N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder. Biomedicines, 2022, 10, 1162.	3.2	1
4	Impact of short warm ischemic time on longitudinal kidney function and survival rate after partial nephrectomy for renal cell carcinoma in patients with pre-existing chronic kidney disease stage III: A multi-institutional propensity score-matched study. European Journal of Surgical Oncology, 2021, 47, 470-476.	1.0	4
5	Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome. Journal of Surgical Oncology, 2021, 123, 204-213.	1.7	18
6	How Does Androgen Deprivation Therapy Affect Mental Health including Cognitive Dysfunction in Patients with Prostate Cancer?. World Journal of Men?s Health, 2021, 39, 598.	3.3	9
7	Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients. World Journal of Men?s Health, 2021, 39, 358.	3.3	9
8	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. Cancer Research and Treatment, 2021, 53, 323-329.	3.0	16
9	Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. Frontiers in Oncology, 2021, 11, 570077.	2.8	9
10	Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma. Medicine (United States), 2021, 100, e26826.	1.0	2
11	The effect of subsequent immunosuppressant use in organ-transplanted patients on prostate cancer incidence: a retrospective analysis using the Korean National Health Insurance Database. BMC Urology, 2021, 21, 112.	1.4	3
12	A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma. PLoS ONE, 2021, 16, e0255965.	2.5	5
13	A Low Geriatric Nutritional Risk Index is Associated with Aggressive Pathologic Characteristics and Poor Survival after Nephrectomy in Clear Renal Cell Carcinoma: A Multicenter Retrospective Study. Nutrition and Cancer, 2020, 72, 88-97.	2.0	19
14	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 187-196.	2.5	24
15	The prognostic role of preoperative serum albumin/globulin ratio in patients with non-metastatic renal cell carcinoma undergoing partial or radical nephrectomy. Scientific Reports, 2020, 10, 11999.	3. 3	15
16	Epithelial Splicing Regulatory Protein (ESPR1) Expression in an Unfavorable Prognostic Factor in Prostate Cancer Patients. Frontiers in Oncology, 2020, 10, 556650.	2.8	7
17	Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study. Frontiers in Oncology, 2020, 10, 568809.	2.8	3
18	Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 558.	2.8	16

#	Article	IF	CITATIONS
19	Intraoperative allogeneic blood transfusion is associated with adverse oncological outcomes in patients with surgically treated non-metastatic clear cell renal cell carcinoma. International Journal of Clinical Oncology, 2020, 25, 1551-1561.	2.2	4
20	The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma. Scientific Reports, 2020, 10, 6967.	3.3	3
21	Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer. Journal of Urology, 2020, 203, 1128-1134.	0.4	19
22	Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database. Investigative and Clinical Urology, 2020, 61, 260.	2.0	5
23	The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma. Investigative and Clinical Urology, 2020, 61, 475.	2.0	7
24	Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study. Investigative and Clinical Urology, 2020, 61, 146.	2.0	0
25	Analysis of the concordance of 20 immunohistochemical tissue markers in metastasectomy lesions in patients with metastatic renal cell carcinoma: A retrospective study using tissue microarray. Investigative and Clinical Urology, 2020, 61, 372.	2.0	3
26	Cause of Mortality After Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-Institutional Study in Korea. Cancer Research and Treatment, 2020, 52, 1242-1250.	3.0	0
27	Developing a prediction model for diseaseâ€free survival from upper urinary tract urothelial carcinoma in the Korean population. Cancer Medicine, 2019, 8, 4967-4975.	2.8	4
28	Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis. BMC Cancer, 2019, 19, 688.	2.6	5
29	Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 859.	2.8	25
30	Survival and clinical prognostic factors in metastatic nonâ€clear cell renal cell carcinoma treated with targeted therapy: A multiâ€institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. Cancer Medicine, 2019, 8, 3401-3410.	2.8	13
31	Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study. Investigative and Clinical Urology, 2019, 60, 195.	2.0	5
32	Correlation Analyses of Computed Tomography and Magnetic Resonance Imaging for Calculation of Prostate Volume in Colorectal Cancer Patients with Voiding Problems Who Cannot Have Transrectal Ultrasonography. BioMed Research International, 2019, 2019, 1-8.	1.9	1
33	Single-Center Analysis of Human Papillomavirus Infection and P16INK4A Expression among Korean Patients with Penile Cancer. BioMed Research International, 2019, 2019, 1-7.	1.9	1
34	Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis. Journal of Bone Metabolism, 2019, 26, 51.	1.3	28
35	Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. PLoS ONE, 2019, 14, e0211105.	2.5	7
36	Tumour heterogeneity in triplet-paired metastatic tumour tissues in metastatic renal cell carcinoma: concordance analysis of target gene sequencing data. Journal of Clinical Pathology, 2019, 72, 152-156.	2.0	6

#	Article	IF	CITATIONS
37	Gender―and cholesterolâ€specific predictive value of body mass index in renal cell carcinoma: A multicenter study. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e36-e42.	1.1	2
38	Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma. Investigative and Clinical Urology, 2019, 60, 432.	2.0	6
39	Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer. Cancer Research and Treatment, 2019, 51, 910-918.	3.0	2
40	Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry. Cancer Research and Treatment, 2019, 51, 758-768.	3.0	9
41	Laparoscopy versus Open Nephroureterectomy in Prognostic Outcome of Patients with Advanced Upper Tract Urothelial Cancer: A Retrospective, Multicenter, Propensity-Score Matching Analysis. Cancer Research and Treatment, 2019, 51, 963-972.	3.0	11
42	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. Investigative and Clinical Urology, 2019, 60, 184.	2.0	2
43	Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis. Scientific Reports, 2018, 8, 2974.	3.3	4
44	Renal capsular invasion is a prognostic biomarker in localized clear cell renal cell carcinoma. Scientific Reports, 2018, 8, 202.	3.3	10
45	Sex-Specific Prognostic Significance of Obesity in Nonmetastatic Clear-Cell Renal-Cell Carcinoma in Korea: A Large Multicenter Cohort Analysis. Clinical Genitourinary Cancer, 2018, 16, e173-e179.	1.9	7
46	Low preoperative serum cholesterol level is associated with aggressive pathologic features and poor cancer-specific survival in patients with surgically treated renal cell carcinoma. International Journal of Clinical Oncology, 2018, 23, 142-150.	2.2	20
47	The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma. Journal of Oncology, 2018, 2018, 1-8.	1.3	9
48	Clear cell papillary renal cell carcinoma: A case report and review of the literature. World Journal of Nephrology, 2018, 7, 155-160.	2.0	1
49	Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. Journal of Korean Medical Science, 2018, 33, e325.	2.5	13
50	Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching. BioMed Research International, 2018, 2018, 1-7.	1.9	9
51	Partial versus Radical Nephrectomy for T1-T2 Renal Cell Carcinoma in Patients with Chronic Kidney Disease Stage III: a Multiinstitutional Analysis of Kidney Function and Survival Rate. Journal of Korean Medical Science, 2018, 33, e277.	2.5	7
52	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. Nutrition and Cancer, 2018, 70, 886-894.	2.0	18
53	A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia. Case Reports in Urology, 2018, 2018, 1-4.	0.3	2
54	Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer., 2018, , 337-352.		0

#	Article	IF	CITATIONS
55	Ageâ€dependent prognostic value of body mass index for nonâ€metastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis. Journal of Surgical Oncology, 2018, 118, 199-205.	1.7	9
56	Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. Journal of Urology, 2018, 200, 989-995.	0.4	16
57	The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients. Japanese Journal of Clinical Oncology, 2018, 48, 835-840.	1.3	8
58	Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. Journal of Hematology and Oncology, 2018, 11, 69.	17.0	32
59	Prostate stem cell antigen mRNA in blood is a predictor of survival after radical prostatectomy in patients with high-risk prostate cancer. Oncotarget, 2018, 9, 26291-26298.	1.8	3
60	Surgical treatment of renal cell carcinoma: Can morphological features of inferior vena cava tumor thrombus on computed tomography or magnetic resonance imaging be a prognostic factor?. International Journal of Urology, 2017, 24, 102-109.	1.0	11
61	Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study. Scientific Reports, 2017, 7, 39562.	3.3	8
62	The effect of predisposing atheroembolic risk factors on renal functional recovery between laparoscopy and open technique in patients with T1-stage renal cell carcinoma who underwent partial nephrectomy: a retrospective comparison study. Japanese Journal of Clinical Oncology, 2017, 47, 876-882.	1.3	1
63	Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy. BMC Cancer, 2017, 17, 364.	2.6	17
64	Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1Âand 2 Using the Korean Renal Cell Carcinoma Database. Clinical Genitourinary Cancer, 2017, 15, e181-e186.	1.9	16
65	Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer, 2017, 15, 100-111.	1.9	28
66	Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BioMed Research International, 2017, 2017, 1-13.	1.9	4
67	Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine. BioMed Research International, 2017, 2017, 1-9.	1.9	6
68	Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review. Journal of Korean Medical Science, 2017, 32, 377.	2.5	11
69	The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry. PLoS ONE, 2017, 12, e0179610.	2.5	48
70	Impact of preoperative thrombocytosis on prognosis after surgical treatment in pathological T1 and T2 renal cell carcinoma: results of a multi-institutional comprehensive study. Oncotarget, 2017, 8, 64449-64458.	1.8	6
71	A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy. Oncotarget, 2017, 8, 93633-93643.	1.8	13
72	Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients. Oncotarget, 2017, 8, 96117-96125.	1.8	3

#	Article	IF	CITATIONS
73	Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naA ve, unresectable metastatic renal cell carcinoma. PLoS ONE, 2017, 12, e0177975.	2.5	2
74	The establishment of KORCC (KOrean Renal Cell Carcinoma) database. Investigative and Clinical Urology, 2016, 57, 50.	2.0	30
75	A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma. Journal of Korean Medical Science, 2016, 31, 1983.	2.5	3
76	Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines. Investigative and Clinical Urology, 2016, 57, 63.	2.0	52
77	Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis. BioMed Research International, 2016, 2016, 1-8.	1.9	20
78	Baseline Chronic Kidney Disease and Ischemic Method of Partial Nephrectomy Are Important Factors for the Short- and Long-Term Deterioration in Renal Function for Renal Cell Carcinoma Staged T1-T2: A Retrospective Single Center Study. BioMed Research International, 2016, 2016, 1-8.	1.9	3
79	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. Journal of Korean Medical Science, 2016, 31, 1976.	2.5	20
80	Surgical margin does not influence recurrence rate in pT1 clear cell renal cell carcinoma after partial nephrectomy: A multicenter study. Journal of Surgical Oncology, 2016, 114, 70-74.	1.7	33
81	Overexpression of <scp>BRCA</scp> 1 or <scp>BRCA</scp> 2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy. Histopathology, 2016, 68, 673-679.	2.9	10
82	Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy. PLoS ONE, 2016, 11, e0151646.	2.5	5
83	A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review. Cancer Research and Treatment, 2016, 48, 838-842.	3.0	4
84	A Study of Relationship of Atheroembolic Risk Factors with Postoperative Recovery in Renal Function after Partial Nephrectomy in Patients Staged T1-2 Renal Cell Carcinoma during Median 4-Year Follow-up. Cancer Research and Treatment, 2016, 48, 288-296.	3.0	3
85	Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy. Cancer Research and Treatment, 2016, 48, 1092-1101.	3.0	24
86	Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea. Journal of Korean Medical Science, 2015, 30, 1150.	2.5	20
87	Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer. PLoS ONE, 2015, 10, e0122498.	2.5	45
88	Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. Journal of Gynecologic Oncology, 2015, 26, 90.	2.2	57
89	Efficacy and safety of holmium laser enucleation of the prostate for extremely large prostatic adenoma in patients with benign prostatic hyperplasia. Korean Journal of Urology, 2015, 56, 218.	1.2	23
90	Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients. Prostate International, 2015, 3, 56-61.	2.3	6

#	Article	IF	CITATIONS
91	A propensity-matched comparison of perioperative complications and of chronic kidney disease between robot-assisted laparoscopic partial nephrectomy and radiofrequency ablative therapy. Asian Journal of Surgery, 2015, 38, 126-133.	0.4	9
92	The prevalence and outcomes of pTO disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer. BMC Urology, 2015, 15, 82.	1.4	7
93	Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. PLoS ONE, 2015, 10, e0135165.	2.5	5
94	Clinicohistological characteristics of renal cell carcinoma in children: A multicentre study. Canadian Urological Association Journal, 2015, 9, 705.	0.6	7
95	Factors Affecting De Novo Urinary Retention after Holmium Laser Enucleation of the Prostate. PLoS ONE, 2014, 9, e84938.	2.5	13
96	Incidence and Risk Factors of 30-Day Early and 90-Day Late Morbidity and Mortality of Radical Cystectomy During a 13-Year Follow-up: A Comparative Propensity-score Matched Analysis of Complications Between Neobladder and Ileal Conduit. Japanese Journal of Clinical Oncology, 2014, 44, 677-685.	1.3	28
97	Localized nonâ€conventional renal cell carcinoma: Prediction of clinical outcome according to histology. International Journal of Urology, 2014, 21, 359-364.	1.0	7
98	A Retrospective Analysis of Incidence and Its Associated Risk Factors of Upper Urinary Tract Recurrence following Radical Cystectomy for Bladder Cancer with Transitional Cell Carcinoma: The Significance of Local Pelvic Recurrence and Positive Lymph Node. PLoS ONE, 2014, 9, e96467.	2.5	15
99	Nonspecific Genitourinary Pain Improves after Prostatectomy Using Holmium Laser Enucleation of Prostate in Patients with Benign Prostatic Hyperplasia: A Prospective Study. PLoS ONE, 2014, 9, e98979.	2.5	3
100	Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Annals of Surgical Oncology, 2013, 20, 4397-4404.	1.5	34
101	Incidence and Risk Factors of Chronic Kidney Disease in Korean Patients with T1a Renal Cell Carcinoma Before and After Radical or Partial Nephrectomy. Japanese Journal of Clinical Oncology, 2013, 43, 1243-1248.	1.3	26
102	Pretreatment assessment of tumor enhancement on contrastâ€enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer, 2010, 116, 2332-2342.	4.1	51
103	Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in highâ€risk prostate cancer. Journal of Surgical Oncology, 2010, 101, 145-148.	1.7	26
104	Prostate Specific Membrane Antigen mRNA in Blood as a Potential Predictor of Biochemical Recurrence after Radical Prostatectomy. Journal of Korean Medical Science, 2010, 25, 1291.	2.5	8
105	Human bloodstream infection caused by Staphylococcus pettenkoferi. Journal of Medical Microbiology, 2009, 58, 270-272.	1.8	24
106	Adult's Wilms' Tumor Mimicking Renal Pelvis Tumor. Korean Journal of Urology, 2007, 48, 558.	0.2	0
107	Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and adjuvant chemotherapy. F1000Research, 0, 9, 1458.	1.6	1
108	Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy. F1000Research, 0, 9, 1458.	1.6	1